Shenmai injection in treating chemotherapy-related cardiotoxicity of breast cancer: a systematic review and meta-analysis

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-17 DOI:10.1016/j.hermed.2024.100936

Ming Feng , Hong Huang , Chang Yao

{"title":"Shenmai injection in treating chemotherapy-related cardiotoxicity of breast cancer: a systematic review and meta-analysis","authors":"Ming Feng , Hong Huang , Chang Yao","doi":"10.1016/j.hermed.2024.100936","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Shenmai injection (SMI) is an established treatment for cardiac diseases, and we performed to evaluate the efficacy of SMI combined with chemotherapy drugs for the treatment of chemotherapy-induced cardiotoxicity.</div></div><div><h3>Methods</h3><div>The primary outcome was abnormal electrocardiogram (ECG), left ventricular ejection fraction (LVEF) and E/A. The secondary outcomes included myocardial injury biomarkers (creatine kinase [CK], creatine kinase MB [CK-MB], and cardiac troponin I [cTnI]) and lipid peroxide markers (superoxide dismutase [SOD], glutathione [GSH], and malondialdehyde [MAD]).</div></div><div><h3>Results</h3><div>Studies indicated that SMI combined with chemotherapy drugs has advantages over chemotherapy drugs alone in reducing the incidence of abnormal ECG (ST-T: RR = 0.613, 95% CI [0.437, 0.862], <em>P</em> = 0.005; extrasystole: RR = 0.527, 95% CI [0.349, 0.798], <em>P</em> = 0.002). Myocardial injury biomarkers in the experimental group were lower than those in the control group (CK: SMD = –2.614, 95% CI [–3.156, –2.071], <em>P</em> = 0.000; CK-MB: SMD = –6.882, 95% CI [–8.982, –4.782], <em>P</em> = 0.000; cTnI: SMD = –3.610, 95% CI [–4.949, –2.271], <em>P</em> = 0.000). Ultrasonic cardiogram analysis showed that the experimental group had a higher LVEF and E/A than the control group (LVEF: SMD = 1.572, 95% CI [1.176, 1.969], <em>P</em> = 0.000; E/A: SMD = 0.280, 95% CI [0.153, 0.407], <em>P</em> = 0.000). Lipid peroxide meta-analysis showed that the experimental group had higher SOD and GSH levels (SOD: weighted mean difference (WMD) = 39.783, 95% CI (32.524, 47.042), <em>P</em> = 0.000; GSH: WMD = 32.960, 95% CI [26.055, 39.865], <em>P</em> = 0.000), and lower malondialdehyde (MDA) (WMD = –4.962, 95% CI [–6.041, –3.883], <em>P</em> = 0.000).</div></div><div><h3>Conclusion</h3><div>SMI is effective in reducing cardiac injury and the incidence of cardiotoxicity.</div></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210803324000939","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Shenmai injection (SMI) is an established treatment for cardiac diseases, and we performed to evaluate the efficacy of SMI combined with chemotherapy drugs for the treatment of chemotherapy-induced cardiotoxicity.

Methods

The primary outcome was abnormal electrocardiogram (ECG), left ventricular ejection fraction (LVEF) and E/A. The secondary outcomes included myocardial injury biomarkers (creatine kinase [CK], creatine kinase MB [CK-MB], and cardiac troponin I [cTnI]) and lipid peroxide markers (superoxide dismutase [SOD], glutathione [GSH], and malondialdehyde [MAD]).

Results

Studies indicated that SMI combined with chemotherapy drugs has advantages over chemotherapy drugs alone in reducing the incidence of abnormal ECG (ST-T: RR = 0.613, 95% CI [0.437, 0.862], P = 0.005; extrasystole: RR = 0.527, 95% CI [0.349, 0.798], P = 0.002). Myocardial injury biomarkers in the experimental group were lower than those in the control group (CK: SMD = –2.614, 95% CI [–3.156, –2.071], P = 0.000; CK-MB: SMD = –6.882, 95% CI [–8.982, –4.782], P = 0.000; cTnI: SMD = –3.610, 95% CI [–4.949, –2.271], P = 0.000). Ultrasonic cardiogram analysis showed that the experimental group had a higher LVEF and E/A than the control group (LVEF: SMD = 1.572, 95% CI [1.176, 1.969], P = 0.000; E/A: SMD = 0.280, 95% CI [0.153, 0.407], P = 0.000). Lipid peroxide meta-analysis showed that the experimental group had higher SOD and GSH levels (SOD: weighted mean difference (WMD) = 39.783, 95% CI (32.524, 47.042), P = 0.000; GSH: WMD = 32.960, 95% CI [26.055, 39.865], P = 0.000), and lower malondialdehyde (MDA) (WMD = –4.962, 95% CI [–6.041, –3.883], P = 0.000).

Conclusion

SMI is effective in reducing cardiac injury and the incidence of cardiotoxicity.

查看原文本刊更多论文

神麦注射液治疗乳腺癌化疗相关心脏毒性：系统综述和荟萃分析

方法主要结果是心电图（ECG）异常、左室射血分数（LVEF）和E/A。次要结果包括心肌损伤生物标志物（肌酸激酶[CK]、肌酸激酶MB[CK-MB]和心肌肌钙蛋白I[cTnI]）和过氧化脂质标志物（超氧化物歧化酶[SOD]、谷胱甘肽[GSH]和丙二醛[MAD]）。结果研究表明，SMI联合化疗药物在降低异常心电图（ST-T：RR=0.613，95% CI [0.437，0.862]，P=0.005；期外收缩：RR=0.527，95% CI [0.349，0.798]，P=0.002）。实验组心肌损伤生物标志物低于对照组（CK：SMD = -2.614，95% CI [-3.156，-2.071]，P = 0.000；CK-MB：SMD = -6.882，95% CI [-8.982，-4.782]，P = 0.000；cTnI：SMD = -3.610，95% CI [-4.949，-2.271]，P = 0.000）。超声心动图分析显示，实验组的 LVEF 和 E/A 均高于对照组（LVEF：SMD=1.572，95% CI [1.176，1.969]，P=0.000；E/A：SMD=0.280，95% CI [0.153，0.407]，P=0.000）。过氧化脂质荟萃分析表明，实验组的 SOD 和 GSH 水平更高（SOD：加权平均差（WMD）= 39.783，95% CI [32.524，47.042]，P = 0.000；GSH：WMD = 32.960，95% CI [26.结论SMI能有效降低心脏损伤和心脏毒性的发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464